I kēia mau lā iho nei, ua loaʻa i ka haʻawina Phase I/II CLINCH a Antengene o ATG-022 (CLDN18.2 antibody-drug conjugate), he maʻi ʻelemakule me ka maʻi ʻaʻai ʻōpū holomua i holomua ma nā laina he nui o ka chemotherapy, immunotherapy a me ka therapy i kuhikuhi ʻia ʻoiai ua nui nā metastases i loaʻa kahi pane piha (CR) ma hope o ka monotherapy ATG-022. Ua hōʻoia ʻia ke kūlana ʻole o ka maʻi e PET/CT i Mei 2025.
I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.
Helu Kelepona：4008803716
ʻIkepili WeChat: 17801183037
Email：myimmnet@163.com
ʻO ATG-022 kahi CLDN18.2 ADC i ʻike ʻia a hoʻomohala ʻia e Antengene. Ma ka ʻaha kūkā ASCO GI 2025 ma mua o kēia makahiki, ua hōʻike ʻo Antengene i ka ʻikepili lapaʻau hou no ATG-022. I nā poʻe maʻi me ka hōʻike ʻana o ka CLDN18.2 waena a kiʻekiʻe (IHC 2+ ≥ 20%), ʻo ka helu pane pahuhopu (ORR) he 42.9%, a ʻo ka helu kaohi maʻi (DCR) he 95.2%. I waena o nā poʻe maʻi me ka hōʻike haʻahaʻa CLDN18.2 (IHC 2+ < 20%), ʻo ka ORR he 30.0%, a ʻo ka DCR he 50.0%. Hōʻike kēia mau ʻikepili e hāʻawi ana ʻo ATG-022 i ka pono lapaʻau koʻikoʻi a me ka palekana maikaʻi ma waena o kahi ʻano o nā pae hōʻike CLDN18.2, me ke kiʻekiʻe, haʻahaʻa, a me ka haʻahaʻa loa. Hōʻike kāna hana antitumor ākea e hiki iā ATG-022 ke hāʻawi i nā pono therapeutic i kahi heluna maʻi ākea i hoʻohālikelike ʻia me nā lāʻau lapaʻau ʻē aʻe i hoʻolālā ʻia no CLDN18.2. I kēia manawa, ke hoʻomau nei ka noiʻi hoʻonui dosis Phase II o ATG-022 ma ka ʻāina nui o Kina a me Australia.
He mea hoʻoikaika nui kēia hoʻokō ʻana o kahi CR i kēia maʻi ʻōpū ʻelemakule, e hōʻike ana i ka hiki ke hoʻōla o ATG-022 ma ke ʻano he lāʻau lapaʻau ADC hou. ʻO ka mea nui, ʻaʻole kēia wale nō ka CR i ʻike ʻia ma ke aʻo ʻana e hoʻomau nei. A hiki i kēia lā, ua ʻike ʻia ʻekolu mau hihia CR, me nā maʻi mai ka ʻāina nui o Kina a me Australia. Ke kakali nei ʻo Antengene i ka hōʻike ʻana i ka ʻikepili hou mai ka haʻawina ATG-022 ma ka ʻAhaʻōlelo ESMO e hiki mai ana i ʻOkakopa 2025.
I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.
Helu Kelepona：4008803716
ʻIkepili WeChat: 17801183037
Email：myimmnet@163.com
Ka manawa hoʻouna: ʻAukake-21-2025